Aregger, Michael http://orcid.org/0000-0001-6443-9870
Lawson, Keith A.
Billmann, Maximillian http://orcid.org/0000-0002-6556-9594
Costanzo, Michael
Tong, Amy H. Y.
Chan, Katherine
Rahman, Mahfuzur
Brown, Kevin R. http://orcid.org/0000-0002-5514-2538
Ross, Catherine
Usaj, Matej
Nedyalkova, Lucy
Sizova, Olga
Habsid, Andrea
Pawling, Judy
Lin, Zhen-Yuan
Abdouni, Hala
Wong, Cassandra J.
Weiss, Alexander
Mero, Patricia
Dennis, James W. http://orcid.org/0000-0002-0295-5877
Gingras, Anne-Claude
Myers, Chad L. http://orcid.org/0000-0002-1026-5972
Andrews, Brenda J. http://orcid.org/0000-0001-6427-6493
Boone, Charles http://orcid.org/0000-0002-3542-6760
Moffat, Jason http://orcid.org/0000-0002-5663-8586
Funding for this research was provided by:
Swiss National Science Foundation | nccr – on the move
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Vanier)
Kidney Cancer Association
Kidney Cancer Research Network of Canada
Ontario Research Foundation
U.S. Department of Health & Human Services | National Institutes of Health (R01HG005084)
National Science Foundation (R01HG005084)
Gouvernement du Canada | Canadian Institutes of Health Research (MOP-142375)
Ontario Research Foundation
Canada Research Chairs
Article History
Received: 8 November 2019
Accepted: 23 April 2020
First Online: 1 June 2020
Competing interests
: J.M., B.J.A. and C.B are shareholders in Northern Biologics. J.M. is a shareholder in Pionyr Immunotherapeutics, is acting chief scientific officer and shareholder in Empirica Therapeutics and is an SAB member and shareholder of Aelian Biotechnology. C.B. is an SAB member of Yumanity Therapeutics.